Technical Data
S8000-01B
Substance P (NK, Neurokinin)
Description:
The tachykinins belong to an evolutionary conserved family of peptide neurotransmitters that share the C-terminal sequence Phe-X-Gly-Leu-Met-NH2 and have an established role in neurotransmission. The mammalian tachykinins include substance P, neurokinin A (NKA) and neurokinin B (NKB) which exert their effects by binding to specific receptors. Tachykinin peptides are important in the mediation of many physiological and pathological processes including inflammation, pain, migraine headache and allergy induced asthma.

Applications:
Suitable for use in ELISA and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
ELISA: 1:10,000
Immunohistochemistry (Vibratome): 1:500-1:1000
Immunohistochemistry (Frozen): 1:300
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG1SP-DE4-21 Affinity Purified
SizeStorageShippingSourceHost
10ug-20CBlue IceHumanMouse
Concentration:
~1mg/ml (after reconstitution)
Immunogen:
Synthetic peptide corresponding RPRPQQFFGLM from human Substance P.
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a lyophilized powder from PBS, pH 7.2, 0.1M glycine. Reconstitute with 10ul sterile ddH2O.
Specificity:
Recognizes human Substance P. No crossreactivity with related tachykinins (human Neurokinin A, Neurokinin B, and Kassinin). Species Crossreactivity: mouse, rat and guinea pig
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Anavi-Goffer S, Coutts AA (2003). Cellular distribution of vanilloid VR1 receptor immunoreactivity in the guinea-pig myenteric plexus. Eur J Pharmacol 458(1-2): 61-71. 2. Patte-Mensah C, Kibaly C, Mensah-Nyagan AG (2005). Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception. Proc Natl Acad Sci U S A 102(25): 9044-9049.